These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34396551)

  • 1. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
    Doyno CR; White CM
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S114-S128. PubMed ID: 34396551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GABA systems, benzodiazepines, and substance dependence.
    Malcolm RJ
    J Clin Psychiatry; 2003; 64 Suppl 3():36-40. PubMed ID: 12662132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sedative-hypnotic drug withdrawal syndrome: recognition and treatment [digest].
    Santos C; Olmedo RE; Kim J
    Emerg Med Pract; 2017 Mar; 19(3 Suppl Points & Pearls):S1-S2. PubMed ID: 28745845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.
    Smith KM; Larive LL; Romanelli F
    Am J Health Syst Pharm; 2002 Jun; 59(11):1067-76. PubMed ID: 12063892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment.
    Santos C; Olmedo RE
    Emerg Med Pract; 2017 Mar; 19(3):1-20. PubMed ID: 28186869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal.
    Feldman R; Autry B; Dukes J; Lofy T; Marchetti G; Patt A; Batterman N; Theobald J
    Clin Toxicol (Phila); 2023 Nov; 61(11):941-951. PubMed ID: 38112312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
    Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
    Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient.
    Wainblat E; Weleff J; Anand A
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):67-74. PubMed ID: 36266201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DARK Classics in Chemical Neuroscience: Methaqualone.
    Inger JA; Mihan ER; Kolli JU; Lindsley CW; Bender AM
    ACS Chem Neurosci; 2023 Feb; 14(3):340-350. PubMed ID: 36651763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.
    Griffiths RR; Johnson MW
    J Clin Psychiatry; 2005; 66 Suppl 9():31-41. PubMed ID: 16336040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benzodiazepine dependence: causalities and treatment options].
    Heberlein A; Bleich S; Kornhuber J; Hillemacher T
    Fortschr Neurol Psychiatr; 2009 Jan; 77(1):7-15. PubMed ID: 19101875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention.
    Harris JT; Roache JD; Thornton JE
    Alcohol Alcohol; 2000; 35(4):319-23. PubMed ID: 10905994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and south Texas.
    Calhoun SR; Wesson DR; Galloway GP; Smith DE
    J Psychoactive Drugs; 1996; 28(2):183-9. PubMed ID: 8811586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenibut exposures and clinical effects reported to a regional poison center.
    McCabe DJ; Bangh SA; Arens AM; Cole JB
    Am J Emerg Med; 2019 Nov; 37(11):2066-2071. PubMed ID: 30878413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of the action of amino acid antagonists by barbiturates and other hypnotic drugs.
    Bowery NG; Dray A
    Br J Pharmacol; 1978 May; 63(1):197-215. PubMed ID: 206305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine mapping of a sedative-hypnotic drug withdrawal locus on mouse chromosome 11.
    Hood HM; Metten P; Crabbe JC; Buck KJ
    Genes Brain Behav; 2006 Feb; 5(1):1-10. PubMed ID: 16436183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for GABA tolerance in barbiturate-dependent and withdrawn mice.
    Gray PL; Taberner PV
    Neuropharmacology; 1985 May; 24(5):437-44. PubMed ID: 2991801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
    Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
    J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.
    Busardò FP; Jones AW
    Curr Neuropharmacol; 2015 Jan; 13(1):47-70. PubMed ID: 26074743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands.
    Korpi ER; Mattila MJ; Wisden W; Lüddens H
    Ann Med; 1997 Aug; 29(4):275-82. PubMed ID: 9375983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.